Autism drug CM-AT shows promise in Long-Term trial for kids
Disease control
Ongoing
This study looks at the long-term safety and effectiveness of CM-AT, an experimental drug, in children with autism aged 3 to 8. It focuses on reducing irritability and social withdrawal. The trial involves 405 children who previously completed a related study.
Phase: PHASE3 • Sponsor: Curemark • Aim: Disease control
Last updated May 06, 2026 16:03 UTC